These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22369215)

  • 1. Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.
    Silver M; Rusk A; Phillips B; Beck E; Jankowski M; Philibert J; Hahn K; Hershey E; McKeegan E; Bauch J; Krivoshik A; Khanna C
    J Vet Intern Med; 2012; 26(2):349-54. PubMed ID: 22369215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.
    Rusk A; Cozzi E; Stebbins M; Vail D; Graham J; Valli V; Henkin J; Sharpee R; Khanna C
    Clin Cancer Res; 2006 Dec; 12(24):7456-64. PubMed ID: 17189419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.
    Vail DM; Husbands BD; Kamerling SG; Simpson H; Kurzman ID; McDonnell A
    J Vet Intern Med; 2012; 26(3):608-13. PubMed ID: 22404399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
    Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
    Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma.
    Sahora AI; Rusk AW; Henkin J; McKeegan EM; Shi Y; Khanna C
    J Vet Intern Med; 2012; 26(5):1169-76. PubMed ID: 22816494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.
    Vail DM; Thamm DH; Reiser H; Ray AS; Wolfgang GH; Watkins WJ; Babusis D; Henne IN; Hawkins MJ; Kurzman ID; Jeraj R; Vanderhoek M; Plaza S; Anderson C; Wessel MA; Robat C; Lawrence J; Tumas DB
    Clin Cancer Res; 2009 May; 15(10):3503-10. PubMed ID: 19417014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
    Yee KW; Hagey A; Verstovsek S; Cortes J; Garcia-Manero G; O'Brien SM; Faderl S; Thomas D; Wierda W; Kornblau S; Ferrajoli A; Albitar M; McKeegan E; Grimm DR; Mueller T; Holley-Shanks RR; Sahelijo L; Gordon GB; Kantarjian HM; Giles FJ
    Clin Cancer Res; 2005 Sep; 11(18):6615-24. PubMed ID: 16166440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
    Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
    Fox E; Maris JM; Widemann BC; Goodspeed W; Goodwin A; Kromplewski M; Fouts ME; Medina D; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
    Clin Cancer Res; 2008 Feb; 14(4):1111-5. PubMed ID: 18281544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
    Hande KR; Hagey A; Berlin J; Cai Y; Meek K; Kobayashi H; Lockhart AC; Medina D; Sosman J; Gordon GB; Rothenberg ML
    Clin Cancer Res; 2006 May; 12(9):2834-40. PubMed ID: 16675578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
    Fox E; Maris JM; Widemann BC; Meek K; Goodwin A; Goodspeed W; Kromplewski M; Fouts ME; Medina D; Cho SY; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
    Clin Cancer Res; 2006 Aug; 12(16):4882-7. PubMed ID: 16914576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.
    Mauer AM; Cohen EE; Ma PC; Kozloff MF; Schwartzberg L; Coates AI; Qian J; Hagey AE; Gordon GB
    J Thorac Oncol; 2008 Jun; 3(6):631-6. PubMed ID: 18520803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.
    Rusk A; McKeegan E; Haviv F; Majest S; Henkin J; Khanna C
    Clin Cancer Res; 2006 Dec; 12(24):7444-55. PubMed ID: 17189418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
    Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
    J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
    Burton JH; Garrett-Mayer E; Thamm DH
    Vet Comp Oncol; 2013 Dec; 11(4):306-15. PubMed ID: 22548975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral melphalan for the treatment of relapsed canine lymphoma.
    Mastromauro ML; Suter SE; Hauck ML; Hess PR
    Vet Comp Oncol; 2018 Mar; 16(1):E123-E129. PubMed ID: 28941072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs.
    Fiocchi SC; Selting KA; Rosenberg MP; Kolli P; Lenaz G; Henry C
    J Vet Intern Med; 2011; 25(4):897-902. PubMed ID: 21736623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy in the management of localized mucocutaneous oral lymphoma in dogs: 14 cases.
    Berlato D; Schrempp D; Van Den Steen N; Murphy S
    Vet Comp Oncol; 2012 Mar; 10(1):16-23. PubMed ID: 22236033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.